Shares of EXACT Sciences Co. (NASDAQ:EXAS) have received a consensus recommendation of “Buy” from the eighteen analysts that are covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $50.97.
Several research analysts have weighed in on EXAS shares. Jefferies Group boosted their price target on EXACT Sciences to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Bank of America set a $56.00 price target on EXACT Sciences and gave the stock a “buy” rating in a research report on Thursday, October 19th. Robert W. Baird reaffirmed a “buy” rating and set a $49.00 price target on shares of EXACT Sciences in a research report on Friday, October 6th. Canaccord Genuity reaffirmed a “buy” rating and set a $60.00 price target (up previously from $45.00) on shares of EXACT Sciences in a research report on Tuesday, October 3rd. Finally, Zacks Investment Research raised EXACT Sciences from a “hold” rating to a “buy” rating and set a $51.00 price target on the stock in a research report on Tuesday, September 26th.
In related news, CEO Kevin T. Conroy sold 137,805 shares of the business’s stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $59.14, for a total transaction of $8,149,787.70. Following the transaction, the chief executive officer now directly owns 967,867 shares of the company’s stock, valued at approximately $57,239,654.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Kevin T. Conroy sold 134,057 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $59.50, for a total value of $7,976,391.50. The disclosure for this sale can be found here. Insiders have sold a total of 610,433 shares of company stock worth $34,341,306 over the last three months. 4.00% of the stock is owned by insiders.
EXACT Sciences (EXAS) traded down $2.44 during trading hours on Tuesday, hitting $52.62. The company’s stock had a trading volume of 6,302,800 shares, compared to its average volume of 1,960,000. The firm has a market cap of $6,300.00, a price-to-earnings ratio of -45.76 and a beta of 0.68. EXACT Sciences has a 52-week low of $16.95 and a 52-week high of $63.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.34 and a quick ratio of 9.98.
EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.07. The firm had revenue of $72.60 million for the quarter, compared to analyst estimates of $65.03 million. EXACT Sciences had a negative return on equity of 30.32% and a negative net margin of 60.71%. The business’s quarterly revenue was up 158.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.36) EPS. equities research analysts forecast that EXACT Sciences will post -1.1 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “EXACT Sciences Co. (EXAS) Receives $50.97 Consensus Target Price from Analysts” was posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.themarketsdaily.com/2018/01/13/exact-sciences-co-exas-receives-50-97-consensus-target-price-from-analysts.html.
About EXACT Sciences
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.